You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》瑞信下调和铂医药-B(02142.HK)目标价至14元 评级「跑赢大市」
阿思达克 06-03 09:51
瑞信发表研究报告指,和铂医药-B(02142.HK)的合作方Immunovant(IMVT.US)日前宣布,计划於今年底至明年初重启对全人源抗FcRn抗体batoclimab的临床研发计划,并考虑透过降低剂量,减少低密度脂蛋白(LDL)胆固醇的影响。

该行指出,目前两家公司都未得出LDL水平的相关临床研究数据,Immunovant的首席医疗官(CMO)更在入职数月後就离任,项目前景维持不明朗,两家公司股价表现亦因此受影响。

瑞信又指,和铂於上市时曾透露将就batoclimab治疗甲状腺相关性眼病(GO)进行研究,但目前未见进展,将目标价降至14元(原本15元),维持「跑赢大市」评级。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account